March 31, 2025
TOPLINE: In a survey of pediatric patients with vitiligo, only 51.4% were offered narrowband ultraviolet B (NB-UVB) phototherapy, and 45.1% received this treatment before the age […]
March 31, 2025
Older adults with severe or refractory psoriatic disease face a unique challenge: Balancing the need for effective systemic treatment with the increased risk for serious infections. […]
March 28, 2025
TOPLINE: Low-dose doxycycline showed comparable efficacy with high-dose treatment in patients with lymphocytic scarring alopecia, with a lower rate of adverse events (AEs) and related discontinuations. […]
March 28, 2025
TOPLINE: Patients with moderate to severe psoriasis treated with ustekinumab and guselkumab showed a trend towards a lower risk for herpes zoster (HZ) and postherpetic neuralgia […]
March 27, 2025
TOPLINE: Hidradenitis suppurativa (HS) treatment choices were shaped by past experiences, healthcare provider recommendations, and patient beliefs in the United Kingdom; a new study emphasised the […]
March 25, 2025
TOPLINE: Nemolizumab was well tolerated and provided lasting relief from itching and disease severity while improving quality of life in patients with prurigo nodularis (PN) over […]
March 24, 2025
A recent analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) data found that beyond the reported associated risks for depression and suicidality, […]
March 21, 2025
ORLANDO, Fla. — A study of automated three-dimensional total-body photography (3D TBP) found that it improved “hit” rates of positive malignant biopsies and reduced unnecessary biopsies […]
March 20, 2025
ORLANDO, Fla. — Dosing of the oral Janus kinase (JAK) inhibitor upadacitinib can be increased or decreased in adult patients with moderate to severe atopic dermatitis […]